{"id":"W4401515835","doi":"10.1038/s41391-024-00865-5","title":"Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study","year":2024,"lang":"en","type":"article","venue":"Prostate Cancer and Prostatic Diseases","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":false,"ca_institutions":"Jewish General Hospital; Université Laval","funders":"Medical Research Council","keywords":"Enzalutamide; Medicine; Prostate cancer; Pembrolizumab; Clinical endpoint; Internal medicine; Cohort; Oncology; Response Evaluation Criteria in Solid Tumors; Cancer; Phases of clinical research; Urology; Surgery; Clinical trial; Immunotherapy; Androgen receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003717015,0.0005287693,0.0008056571,0.000238181,0.0004717767,0.0003419199,0.0001305863,0.00005505159,0.00006031782],"category_scores_gemma":[0.0001773084,0.0003280175,0.0001732677,0.0005420406,0.0006265311,0.0003033654,0.0001040768,0.0002790386,0.000001166945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000389798,"about_ca_system_score_gemma":0.002277152,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000477609,"about_ca_topic_score_gemma":0.0002060241,"domain_scores_codex":[0.9966947,0.0001599466,0.0007225678,0.0009385272,0.0007871357,0.000697159],"domain_scores_gemma":[0.9981417,0.000442638,0.0002305699,0.0004104944,0.0003058856,0.0004687057],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.08059613,0.006184154,0.2125235,0.04658282,0.005779826,0.001311313,0.05493991,0.0006209764,0.01508544,0.0009113863,0.004663814,0.5708007],"study_design_scores_gemma":[0.2660062,0.05837015,0.3863459,0.04514086,0.03754902,0.0004827018,0.04087819,0.04168852,0.06377395,0.02020214,0.03283578,0.006726604],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9184117,0.06230706,0.00001305479,0.002521415,0.0003372015,0.01081888,0.005438352,0.0001045218,0.00004781868],"genre_scores_gemma":[0.9870609,0.004141375,0.0001173951,0.0002475828,0.0001131154,0.006198164,0.0001654993,0.0001017957,0.001854149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5640742,"threshold_uncertainty_score":0.9999172,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04024679531211643,"score_gpt":0.3976870605521131,"score_spread":0.3574402652399966,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}